Substantial survival increase after highly active antiretroviral therapy for HIV-1 infection

Research published in this week's issue of The Lancet highlights the substantial increased survival for people with HIV-1 since the introduction of highly active antiretroviral therapy (HAART) in 1997. However the study also shows a shift in risk profiles compared with earlier data-people over 45 years no longer appear to have reduced survival compared with younger people, and individuals who acquire HIV-1 infection from injecting drug use have mortality rates four times greater than infection acquired from homosexual contact.

Using data from a large collaboration of 22 studies in Europe, Australia, and Canada (CASCADE), Kholoud Porter from the UK Medical Research Council Clinical Trials Unit and colleagues assessed the continuing effect of HAART on survival and progression to AIDS after HIV-1 seroconversion (the point at which antibodies to HIV-1 infection are detectable in blood). The investigators compared the effects of age at seroconversion, exposure category, sex, and presentation during acute HIV-1 infection pre-1997 (pre-HAART), in 1997-98 (limited use of HAART), and 1999-2001 (widespread use of HAART).

Compared with pre-1997 data, death rates were reduced by 50% in 1997, and by over 80% by 2001; during this time use of HAART therapy increased from 22% in 1997 to 57% in 2001. The largest reduction in mortality occured soon after HAART first became available in 1997.

By contrast with the pre-HAART era, injecting drug users had death rates four times greater in 1999-2001 than men infected through homosexual contact. Whereas pre-1997 the risk of AIDS was higher in those aged 45 years or older at seroconversion than in people who were 16-24 years, there was little evidence of a difference in risk by age in 1999-2001.

Kholoud Porter comments: "Now that HAART therapy is available, 9 out of 10 people infected with HIV-1 can expect to survive more than 10 years, regardless of their age. Earlier diagnosis provides opportunities t

Contact: Joe Santangelo

Page: 1 2

Related medicine news :

1. Substantial increase in breast cancer risk from combination hormone replacement therapy
2. Substantial increase in death rate after bypass surgery for people with anaemia
3. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
4. Hormonal treatment improves survival in high-risk prostate cancer patients
5. Lack of clinical trial participation may contribute to lower survival rates
6. Alcohol relapse adversely affects 10-year liver transplant survival
7. Donor age has no affect on long-term liver transplant survival
8. Specialist care gives better rate of survival
9. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
10. New treatment options for some difficult cancers improve survival and quality of life
11. Medical technologies may hinder rather than help newborn survival

Post Your Comments:

(Date:5/14/2019)... ... 14, 2019 , ... A coalition of businesses, governments and ... issues – ‘big data’. At a news conference today, Texas-based HMS ... and Southern Methodist University (SMU) announced the U.S. launch of research which will ...
(Date:5/14/2019)... ... May 14, 2019 , ... Forty-two billion ... products and procedures, according to market analysis company Orbis Research. “Treatments certainly can ... Advanced Dermatology PC , “but for our skin, there’s free super-potent anti-aging ...
(Date:5/14/2019)... ... May 14, 2019 , ... ChoiceSpine LLC, a privately-held ... U.S. Food and Drug Administration (FDA) to market TIGER SHARK C interbody device ... for use together or separately in cervical spinal fusion procedures. , “BOOMERANG ...
(Date:5/14/2019)... ... ... Dr. Steven Shoshany has been treating patients experiencing both acute and long term ... device, becoming the first chiropractor in Manhattan to do so. Since January, Dr. Shoshany ... treating pain and injuries, into his downtown practice. He recently finished designing a new ...
(Date:5/14/2019)... ... 14, 2019 , ... Survival rates decline every year for patients with undiagnosed ... , For each year diagnosis is delayed, the risk of disease-specific death rises by ... of Oral and Maxillofacial Surgery – the official journal of the American Association of ...
Breaking Medicine News(10 mins):
(Date:5/16/2019)... and FORT WORTH, Texas (PRWEB) , ... May 16, 2019 , ... ... raised $21.7 Million in a Series B financing round. The Series B is ... Partners, participating. , Actuate will use the proceeds of the financing to expand the ...
(Date:5/16/2019)... FRANCISCO (PRWEB) , ... May 16, 2019 , ... ... patient engagement, today announced it has launched Mobile Patient Intake. This new solution ... complete the intake process at their own convenience, on their device of choice, ...
(Date:5/16/2019)... ... May 16, 2019 , ... Though Nefertiti’s Secret—a book by nationally ... via Amazon since April 2019, the author is officially celebrating its publication with a ... invite-only from 5 to 6:30 p.m., then opens to the public at 7 p.m. ...
Breaking Medicine Technology:
Cached News: